SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing
March 01 2023 - 9:00AM
Business Wire
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company
in the healthcare space, today announced a new partnership with
QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology
with the SOPHiA DDM™ platform to enhance tumor analysis through
next-generation sequencing (NGS).
The partnership will allow customers to order QIAseq panels that
can be processed through SOPHiA DDM™, a cloud-based platform that
analyzes data from various sources to enable entirely new research
perspectives. The partnership will initially support somatic
variant detection (an alteration in DNA that occurs after birth)
using QIAseq Targeted DNA Pro panels for homologous recombination
repair (HRR), a special type of biomarker test to find tumors that
have certain mutations that may make them sensitive to PARP
inhibitors in oncology.
“SOPHiA’s mission is to democratize data-driven medicine. To get
there, we are partnering with reagent manufacturers so that our
deep expertise in genomic analysis complements their solutions,”
said Kevin Puylaert, VP Business Development at SOPHiA GENETICS.
“We have a strong and longstanding relationship with QIAGEN and
have used their products as part of our ‘bundle solution’ for
years. QIAGEN’s amplicon-targeted NGS technology has an outstanding
reputation to be among the best. We are taking full advantage of
the performance of both solutions in this collaboration and are
very optimistic about the positive impact on medicine and
research.”
“Our Platform Partnership Program will enable more customers to
benefit from the high quality of the QIAGEN NGS preparation kits
through the use of a wider range of analytics solutions to address
their unique analysis and interpretation needs,” said Thomas
Schweins, Senior Vice President of the Life Sciences Business Area
at QIAGEN. “SOPHiA GENETICS is our first partner thanks to their
deep and unique expertise and reputation. We look forward to
offering our customers a combination of best-in-class solutions and
expanding our collaboration.”
The applications of SOPHiA DDM™ will support a wide range of
applications using QIAGEN kits. The goal is to allow customers to
use SOPHiA GENETICS’s Set-Up Program, an efficient and reliable
process designed to establish and demonstrate the analytical
performance of any test prior to it being carried out. This will
enable customers to better and more efficiently design new
workflows using QIAseq technologies.
The partnership with SOPHiA GENETICS is planned to be expanded
to other areas of analysis, including the use of QIAseq panels
custom-made solutions. It is the inaugural partnership in QIAGEN’s
QIAseq Platform Partnership.
NGS has the potential to revolutionize the diagnosis and
treatment of cancers and rare diseases but creates extremely large,
complex, and noisy datasets for analysis. Without the right
analytical technology, pinpointing causative variants and obtaining
actionable insights from NGS data requires specialist skills,
multiple resources, and considerable time. The SOPHiA DDM™ Platform
uses machine learning with patented methods to efficiently call,
annotate, and pre-classify variants from raw NGS data.
User-friendly features streamline prioritization, simplify
interpretation, and expedite reporting.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing data-driven medicine as the standard for medical
care and life-sciences research. It is the creator of the SOPHiA
DDM™ Platform, a cloud-native platform capable of analyzing data
and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions.
For more information visit SOPHiAGENETICS.COM or connect on
Twitter, LinkedIn, Facebook, and Instagram. Where others see
data, we see answers.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of December
31, 2022, QIAGEN employed approximately 6,200 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures, unless specified otherwise. QIAseq
Targeted DNA Panels are intended for molecular biology
applications. These products are not intended for the clinical
diagnosis, prevention, or treatment of any disease. The information
in this press release is about products that may or may not be
available in different countries and, if applicable, may or may not
have received approval or market clearance by a governmental
regulatory body for different indications for use. Please contact
support@sophiagenetics.com to obtain the appropriate product
information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management’s beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230301005228/en/
SOPHiA Genetics:
Investor Relations Katherine Bailon
ir@sophiagenetics.com
Public Relations Nick Puleo npuleo@comsint.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024